Phosplatin Therapeutics LLC New York City, NY - 10019

Phosplatin Therapeutics LLC is categorized under Commercial Biotechnical Research in New York City, NY and active since 2010.

Phosplatin Therapeutics LLC was established in 2010, and today employs 1 to 4, earning $0 to $49.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.

If you are seeking more information, feel free to contact Robert E Fallon at the company’s single location by writing to 1350 Avenue Of, New York City, New York NY 10019 or by phoning (646) 380-2441. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Phosplatin Therapeutics LLC
Contact Person: Robert E Fallon
Address: 1350 Avenue Of, New York City, New York 10019
Phone Number: (646) 380-2441
Website Address: phosplatin.com
Annual Revenue (USD): $0 to $49.999
Founded: 2010
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2B (Business to Business)
Business Category: Commercial Biotechnical Research
SIC Code: 8731
NAICS Code: 541711
Share This Business:

Phosplatin Therapeutics LLC was started in 2010 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $0 to $49.999 per annum.

Feel free to contact Robert E Fallon for inquiries that concern Phosplatin Therapeutics LLC by calling the company number (646) 380-2441, as your correspondence is most welcome. Additionally, the physical location of the single location of Phosplatin Therapeutics LLC can be found at the coordinates 40.750964,-73.994447 as well as the street address 1350 Avenue Of in New York City, New York 10019.

For its online presence, you may visit Phosplatin Therapeutics LLC’s website at phosplatin.com and engage with its social media outlets through on Twitter and on Facebook.